Ausgabe 12/2016
Inhalt (26 Artikel)
PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer
Francesco Ceci, Paolo Castellucci, Cristina Nanni, Stefano Fanti
Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer
Sarah M. Schwarzenböck, Matthias Eiber, Günther Kundt, Margitta Retz, Monique Sakretz, Jens Kurth, Uwe Treiber, Roman Nawroth, Ernst. J. Rummeny, Jürgen E. Gschwend, Markus Schwaiger, Mark Thalgott, Bernd J. Krause
Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer
Thomas Pyka, Shozo Okamoto, Marielena Dahlbender, Robert Tauber, Margitta Retz, Matthias Heck, Nagara Tamaki, Markus Schwaiger, Tobias Maurer, Matthias Eiber
Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand
Stefano Boschi, Jason T. Lee, Seval Beykan, Roger Slavik, Liu Wei, Claudio Spick, Uta Eberlein, Andreas K. Buck, Filippo Lodi, Gianfranco Cicoria, Johannes Czernin, Michael Lassmann, Stefano Fanti, Ken Herrmann
Malignant lipogenesis defined by 11C-acetate PET/CT predicts prostate cancer-specific survival in patients with biochemical relapse after prostatectomy
Naresh Regula, Michael Häggman, Silvia Johansson, Jens Sörensen
Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer
Catharina M. L. Zegers, Frank J. P. Hoebers, Wouter van Elmpt, Judith A. Bons, Michel C. Öllers, Esther G. C. Troost, Daniëlle Eekers, Leo Balmaekers, Marlies Arts-Pechtold, Felix M. Mottaghy, Philippe Lambin
The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy
Shozo Okamoto, Tohru Shiga, Koichi Yasuda, Shiro Watanabe, Kenji Hirata, Ken-ichi Nishijima, Keiichi Magota, Katsuhiko Kasai, Rikiya Onimaru, Kazuhiko Tuchiya, Yuji Kuge, Hiroki Shirato, Nagara Tamaki
TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib
Kung-Chu Ho, Yu-Hua Dean Fang, Hsiao-Wen Chung, Yuan-Chang Liu, John Wen-Cheng Chang, Ming-Mo Hou, Cheng-Ta Yang, Nai-Ming Cheng, Tzu-Pei Su, Tzu-Chen Yen
ImmunoPET to help stratify patients for targeted therapies and to improve drug development
Françoise Kraeber-Bodere, Clément Bailly, Michel Chérel, Jean-François Chatal
ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer
Haiyan Sun, Christopher G. England, Reinier Hernandez, Stephen A. Graves, Rebecca L. Majewski, Anyanee Kamkaew, Dawei Jiang, Todd E. Barnhart, Yunan Yang, Weibo Cai
How reliable is 18FDG PET for predicting the onset of Huntington’s disease?
Andrea Ciarmiello
Striatal hypometabolism in premanifest and manifest Huntington’s disease patients
Diego Alfonso López-Mora, Valle Camacho, Jesús Pérez-Pérez, Saül Martínez-Horta, Alejandro Fernández, Frederic Sampedro, Alberto Montes, Gloria Andrea Lozano-Martínez, Beatriz Gómez-Anson, Jaime Kulisevsky, Ignasi Carrió
Comparison between MRI-based attenuation correction methods for brain PET in dementia patients
Jorge Cabello, Mathias Lukas, Elena Rota Kops, André Ribeiro, N. Jon Shah, Igor Yakushev, Thomas Pyka, Stephan G. Nekolla, Sibylle I. Ziegler
Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain
Claire Feeney, Gregory Scott, Joel Raffel, S. Roberts, Christopher Coello, Amy Jolly, Graham Searle, A. P. Goldstone, David J. Brooks, Richard S. Nicholas, William Trigg, Roger N. Gunn, David J. Sharp
Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351
Ryuichi Harada, Shozo Furumoto, Tetsuro Tago, Furukawa Katsutoshi, Aiko Ishiki, Naoki Tomita, Ren Iwata, Manabu Tashiro, Hiroyuki Arai, Kazuhiko Yanai, Yukitsuka Kudo, Nobuyuki Okamura
Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease
Rawaha Ahmad, Andrey Postnov, Guy Bormans, Jan Versijpt, Mathieu Vandenbulcke, Koen Van Laere
18F-FDG PET/CT imaging factors that predict ischaemic stroke in cancer patients
Jahae Kim, Kang-Ho Choi, Ho-Chun Song, Joon-Tae Kim, Man-Seok Park, Ki-Hyun Cho
Feasibility and acceptance of simultaneous amyloid PET/MRI
Lisa Schütz, Donald Lobsien, Dominik Fritzsch, Solveig Tiepolt, Peter Werner, Matthias L. Schroeter, Jörg Berrouschot, Dorothee Saur, Swen Hesse, Thies Jochimsen, Michael Rullmann, Bernhard Sattler, Marianne Patt, Hermann-Josef Gertz, Arno Villringer, Joseph Claßen, Karl-Titus Hoffmann, Osama Sabri, Henryk Barthel
A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism
Flavia Niccolini, Marios Politis
Guidelines to PET measurements of the target occupancy in the brain for drug development
Akihiro Takano, Andrea Varrone, Balázs Gulyás, Piero Salvadori, Antony Gee, Albert Windhorst, Johnny Vercouillie, Guy Bormans, Adriaan A. Lammertsma, Christer Halldin
Comments on Van den Wyngaert et al., The EANM practice guidelines for bone scintigraphy
Sven-Åke Starck, Lene Rosendahl
Strategy based on kinetics of O-(2-[18F] fluoroethyl)-L-tyrosine ([18F] FET)
Masashi Kameyama, Yumi Umeda-Kameyama
99mTc-DPD-scintigraphy with intense uptake in fat tissue caused by AL-amyloidosis
M. Zoller, G. Hajnos, R. Burkhard, S. Kneifel
Paraneoplastic syndrome demonstrated on 99mTc-HMDP bone scan
Sophie Lancelot, Francesco Giammarile, Agnes Tescaru
In memoriam: Prof. Ignac Fogelman (04.09.1948 – 05.07.2016)
Gopinath Gnanasegaran, Frédéric Paycha, Tim Van den Wyngaert, Ora Israel